36 results about "Mannan-binding lectin" patented technology

The present invention relates to pharmaceutical compositions comprising MBL and / or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200 μg / ml protein containing material, wherein mannan binding lectin (MBL) and / or MBL variants constitutes at least 35% (w / w) of the total protein; or to compositions comprising at least 400 μg / ml mannan binding lectin (MBL) and / or MBL variants. In addition the invention relates to pharmaceutical compositions comprising MBL and / or MBL variants and divalent cations. The invention also describes methods of preparing said compositions.The pharmaceutical compositions according to the invention may for example be used in methods of treatment of a number of different clinical conditions including infections. Uses of the compositions for preparation of medicaments for treatment of a clinical condition are also described.

The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylaxis and / or treatment of infection. In particular the invention relates to prophylaxis and / or treatment of infection in an individual having an immunocompromised condition; and / or an individual being at risk of acquiring an immunocompromised condition resulting from a medical treatment. The present invention is particular relevant for prophylaxis and / or treatment of infection in individuals suffering from neutropenia, in particular as prophylaxis and / or treatment of infection in individuals receiving or going to receive chemotherapy or similar treatment. The individuals may be treated independent on their serum MBL level, and it has been shown that in particular individuals having a serum MBL level in the range of from 50 ng / ml serum to 500 ng / ml serum may benefit from the prophylaxis and / or treatment.

The present invention relates to substantially pure mannan-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Furthermore, the present invention relates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositions comprising MASP-2 and / or MASP-2 fragments. In addition the present invention relates to inhibitors of MASP-2 and pharmaceutical compositions comparing such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention.

Various antibodies with different binding characteristics for MBL A or MBL B bound to mannan or MBL A or MBL B bound to an antibody against MBL are provided. Also provided are methods for selecting antibodies against MBL with different binding characteristics and methods and kits for using these antibodies to measure MBL capable of binding to mannan or oligomerized MBL and abnormal, poorly oligomerized MBL in a sample. The methods and kits are useful in diagnosing increased susceptibility to and exacerbation of infections and autoimmune diseases.

Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.

The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.

The invention discloses the application of MBL in the preparation of drugs for preventing or treating effector T cell-induced diseases, and belongs to the technical field of new applications of mannan-binding lectins. The gist of the technical solution of the present invention is: the application of MBL in the preparation of drugs for the prevention or treatment of infectious diseases, autoimmune diseases or / and allergic diseases caused by effector T cells, wherein MBL inhibits the proliferation of effector T cells by enhancing iTreg cells achieve the efficacy of the drug. The present invention obtains the new factor that regulates Tregs cell inhibitory function through research, namely MBL directly strengthens Tregs cell to effector T cell proliferation inhibitory effect; The present invention highlights a kind of new function of MBL, not only plays an important anti-inflammatory role in innate immunity Infection, and in the intervention of Tregs cell function, it may be a target for the treatment of various autoimmune and inflammatory diseases.

The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and / or curative treatment of patients admitted to intensive care units (ICUs).

The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylaxis and / or treatment of infection. In particular the invention relates to prophylaxis and / or treatment of infectionin an individual having an immunocompromised condition; and / or an individual being at risk of acquiring an immunocompromised condition resulting from a medical treatment. The present invention is particularly relevant for prophylaxis and / or treatment of infection in individuals suffering from neutropenia, in particular as prophylaxis and / or treatment of infection in individuals receiving or goingto receive chemotherapy or similar treatment. The individuals may be treated independent on their serum MBL level, and it has been shown that in particular individuals having a serum MBL level in therange of from 50 ng / ml serum to 500 ng / ml serum may benefit from the prophylaxis and / or treatment.

The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.

The present invention relates to the use of subunits and oligomers of mannan-binding lectin (MBL) in prophylactic and / or curative treatment of infections in an individual receiving TNF-inhibiting treatment, in particular TNF-α-inhibiting treatment. The MBL may be administered together with an antimicrobial agent, for example as a kit-of-parts.

The present invention relates to Surfactant Protein D (SP-D) or nucleic acids encoding SP-D or variants thereof such as surfactant protein A or mannan binding lectin for use in the treatment and / or prevention of a parasitic infection. Methods for determining the presence of a parasitic infection by determining levels of SP-D in a sample are also disclosed. Also disclosed are helminths for treating allergy, inflammation or infection.